Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428238 | 0.86 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7415776 | 0.85 | CHRM3 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7421543 | 0.84 | OPRM1 (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7414392 | 0.84 | CHRM3 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1428246 | 0.84 | CHRM3 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7425414 | 0.82 | TP53 (0.58) | LMNATP53ALDH1A1KDM4EKMT2A | |
| SCHEMBL29513187 | 0.78 | ALDH1A1 (0.37) | OPRM1SLC6A4LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL8701093 | 0.76 | PKM (0.38) | OPRM1LMNATP53HSD17B10SMN1; SMN2 | |
| SCHEMBL2986864 | 0.76 | ALDH1A1 (0.46) | LMNATP53ALDH1A1KMT2AMAPT | |
| SCHEMBL244149 | 0.73 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9227968-B2 | Method of treatment or prophylaxis of inflammatory pain | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9018207-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-28 | — | — | US | disclosed |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-08-14 | — | — | US | disclosed |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| US-8722675-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-13 | — | — | US | disclosed |
| US-20130296350-A1 | Method of Treatment or Prophylaxis | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | disclosed |
| US-8492382-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| US-8404686-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-03-26 | — | — | US | disclosed |
| US-20110318329-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | UNIVERSITY OF QUEENSLAND (AU) | 2010-11-18 | — | — | US | disclosed |
| US-7828840-B2 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | MED INSTITUTE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7795275-B2 | Method of treatment or prophylaxis | UNIQUEST PTY LIMITED (AU) | 2010-09-14 | — | — | US | disclosed |
| US-20090177267-A1 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2009-07-09 | — | — | US | disclosed |
| EP-1830869-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223741-A1 | Method of treatment or prophylaxis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-10-05 | — | — | US | disclosed |
| WO-2006066361-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-06-29 | — | — | WO | disclosed |
| US-5789415-A | Azacyclic-heterocyclic compounds as angiotension II receptor antagonists | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296350-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | OPRM1 243/4885OPRD1 214/4885OPRK1 66/4885 |
| US-20060223741-A1 | Method of treatment or prophylaxis | AGTR2, AGTR1, NTSR2 | OPRM1 243/4885OPRD1 214/4885OPRK1 66/4885 |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | OPRM1 96/4885OPRD1 125/4885OPRK1 44/4885 |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | AGTR2, AGTR1, BDKRB2 | OPRM1 189/4885OPRD1 129/4885OPRK1 23/4885 |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | OPRM1 243/4885OPRD1 214/4885OPRK1 66/4885 |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | OPRM1 177/4885OPRD1 151/4885OPRK1 24/4885 |
| US-20110318329-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | AGTR2, AGTR1, NTSR2 | OPRM1 243/4885OPRD1 214/4885OPRK1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.